DB75 targets PRMT1 to suppress liver metastasis and synergizes with PD-L1 blockade for enhanced therapeutic efficacy.
DB75 targets PRMT1 to suppress liver metastasis and synergizes with PD-L1 blockade for enhanced therapeutic efficacy.
Sumin Sun,Haili Hu,4 Authors,Liming Chen
2025 · DOI: 10.1016/j.intimp.2025.115327
International Immunopharmacology · 0 Citations
TLDR
This study elucidates the mechanism by which DB75 suppresses BCLM and provides preclinical evidence for PD-L1 blockade-based combinatorial immunotherapy, which was significantly superior to anti-PD-L1 mAb monotherapy.